Inclusion Criteria:

• Patients ≥ 18 years of age.
• Patients must have solid tumors 
• Able to provide a tumor tissue sample.
• Must have 1 measurable lesion according to RECIST Version 1.1.
• Must have ECOG performance status of 0-1.
• Adequate organ and bone marrow function.
• If a female of childbearing potential, must have a negative pregnancy test prior to enrollment. 
• Must provide signed consent to participate in the study and is willing to comply with study-specific procedures.

Exclusion Criteria:

• Received anticancer therapy, therapy for TGCT, including investigational therapy, within 2 weeks or 28 days for therapies with half-life longer than 3 days prior to the administration of study drug. 
• Unresolved toxicity (> Grade 1 or baseline) from previous anticancer or TGCT therapy, excluding alopecia. 
• Known active CNS metastases. 
• History or presence of clinically relevant cardiovascular abnormalities. 
• Systemic arterial or venous thrombotic or embolic events. 
• QT interval corrected by Fridericia's formula (QTcF) >450 ms in males or > 470 ms in females or history of long QT syndrome. 
• Left ventricular ejection fraction (LVEF) < 50%. 
• Concurrent treatment with proton-pump inhibitor. 
• Major surgery within 2 weeks of the first dose of study drug. 
• Malabsorption syndrome or other illness that could affect oral absorption. 
• Known human immunodeficiency virus, active hepatitis B, active hepatitis C, or active mycobacterium tuberculosis infection. 
• If female, the patient is pregnant or lactating.
• Known allergy or hypersensitivity to any component of the study drug.
• Any other clinically significant comorbidities.